Skip to main content
Zealand Pharma logo

Zealand Pharma — Investor Relations & Filings

Ticker · ZEAL ISIN · DK0060257814 LEI · 549300ITBB1ULBL4CZ12 CO Professional, scientific and technical activities
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2023-12-04 Director's Dealing
Country DK Denmark
Listing CO ZEAL

About Zealand Pharma

https://www.zealandpharma.com/

Zealand Pharma is a biotechnology company specializing in the discovery, design, and development of innovative peptide-based medicines. The company's primary focus is on advancing treatments for obesity and metabolic diseases, with a strategic goal to become a leader in this field. Its pipeline includes multiple candidates targeting obesity, such as petrelintide (a long-acting amylin analog) and survodutide (a glucagon/GLP-1 dual agonist licensed to a partner). Beyond metabolic health, Zealand Pharma develops therapies for rare diseases, including dasiglucagon for congenital hyperinsulinism and glepaglutide for short bowel syndrome. The company also has programs in chronic inflammation. Leveraging its expertise in peptide science, the company aims to create next-generation therapeutics to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (the CFO, Henriette Wennicke) at Zealand Pharma. It details the vesting and allocation of Performance Stock Units. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing, which covers personal share transactions by company executives.
2023-12-04 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short company announcement (No. 41 / 2023) from Zealand Pharma, explicitly stating the 'Total number of shares and voting rights' as of November 30, 2023, in compliance with the Danish Capital Markets Act. This type of filing, which reports specific, periodic changes related to share capital or voting rights, is not explicitly covered by the main categories like 10-K, ER, or IR. It is a regulatory disclosure concerning the capital structure. Since it is a specific regulatory update that doesn't fit the definitions for Director's Dealing (DIRS), Share Issue (SHA), or Transaction in Own Shares (POS) which usually involve specific transactions, the most appropriate general category for miscellaneous regulatory disclosures that don't fit elsewhere is Regulatory Filings (RNS). However, given the content is purely about the total share count, which is a fundamental aspect of capital structure reporting, and it is not a general announcement of a report (RPA), RNS serves as the best fit among the provided options for this specific, non-standard regulatory disclosure.
2023-11-30 English
Share Issue/Capital Change 2023
Share Issue/Capital Change Classification · 99% confidence The document is a company announcement from Zealand Pharma dated November 16, 2023, titled 'Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants'. The content explicitly details an increase in share capital due to the exercise of employee warrants, resulting in the issuance of new shares and an update to the total share capital. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not a general financing update (CAP) as it is a specific consequence of an existing incentive program, nor is it a transaction in own shares (POS) which typically refers to buybacks or treasury stock transactions.
2023-11-16 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 98% confidence The document is titled "Standard form for notification of major holdings" and explicitly mentions sections related to the "Capital Markets Act" and the requirement to report changes in "voting rights or share capital" and "financial instruments." This structure is characteristic of a mandatory regulatory filing concerning significant ownership changes in a company's shares. This directly corresponds to the definition of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2023-10-20 English
Zealand Pharma major shareholder announcement: Polar Capital
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement from Zealand Pharma regarding a change in major shareholding by Polar Capital LLP. It explicitly references the Danish Capital Markets Act and provides details on the percentage of voting rights held. This fits the definition of a Major Shareholding Notification (MRQ).
2023-10-20 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short company announcement (No. 36 / 2023) from Zealand Pharma, dated September 29, 2023. It explicitly states the 'Total number of shares and voting rights' as of that date, referencing compliance with the Danish Capital Markets Act. This type of announcement, detailing the current share count and voting rights, is a specific regulatory disclosure. It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). It most closely aligns with a notification regarding capital structure or share changes, but specifically focuses on the total number of shares outstanding for voting purposes. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it relates to the capital structure, although 'RNS' (Regulatory Filings) is a strong fallback. Since the core content is the official count of shares and voting rights, which directly impacts capital structure reporting, SHA is the most precise classification for this type of mandatory disclosure regarding the total number of shares.
2023-09-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.